Leadership

Michael Meyers, MPH – Interim CEO

Mr. Meyers has served as interim CEO of Tivorsan since December 2016. Mr. Meyers is Managing Director and Head of Investment Banking at T.R. Winston & Company, with over 23 years of experience in investment banking, venture capital and asset management. Prior to joining T.R. Winston, Mr. Meyers was the CEO and Chief Investment Officer of Arcoda Capital Management LP, a healthcare focused fund. Prior to founding Arcoda in 2007, Mr. Meyers was a Partner and Portfolio Manager with GoldenTree Asset Management LP, a $17 billion multi-strategy asset management firm; a founding Managing Partner, Portfolio Manager and Sector Head of Healthcare of Trivium Capital Management LLC; and a Managing Director, Partner and member of the Board of Directors of Global Biomedical Partners AG, a life sciences venture capital and private equity firm located in New York and Zurich, Switzerland that was acquired by HBM Bioventures in 2003. Mr. Meyers serves on the Board of Trustees of the Ronald Reagan UCLA Medical Center, the Board of Councilors of the University of Southern California’s School of Dramatic Arts and the Board of Directors of The JED Foundation.

John P. Nicholson, MD, FACC, MBA (Brown ‘72) – Chairman

Dr. Nicholson has over twenty years experience as a health care and life sciences investor, analyst and portfolio fund manager. He is also cardiologist and Clinical Associate Professor of Medicine at Cornell University.

Joel B. Braunstein, MD, FACC, MBA – Director

Dr. Braunstein, a Johns Hopkins-trained cardiologist, is co-founder and partner of LifeTech Research, a technology research and development firm. Dr. Braunstein is an Adjunct Assistant Professor of Medicine at Yale University. He has co-founded and served as a senior executive for two biotechnology companies, including Centegen, an anti-infective company, and C2N Diagnostics, a rapidly-growing Alzheimer’s drug and biomarker discovery company. He also serves as a corporate director to medical device companies: Correx, Inc and NexGen Medical Systems, Inc.

Jim Connolly – Director

Mr. Connolly has spent more than 23 years at Wyeth (now part of Pfizer), where he served in a series of senior management, commercial, business development and finance positions, including Executive Vice President and GM, Wyeth Vaccines and President, Wyeth Canada. He was President and CEO of Aeras, a not-for-profit biotech developing biologics and vaccines for TB and other neglected diseases. He was also an advisor and consultant to a variety of pharma, biotech and investment organizations. Mr. Connolly currently serves on the Boards of PaxVax, Vaxess Technologies and Aeras.

Justin Fallon, PhD – Scientific Founder; Brown University, Professor; Director

Dr. Fallon is the primary inventor of the biglycan-related technology. He is an internationally recognized authority on the neuromuscular junction and muscle cell biology. Dr. Fallon received his undergraduate degree from Colgate University, PhD in Cell Biology at the University of Pennsylvania, and performed post-doctoral research in neurobiology at both University College London and Stanford University. He is the recipient of numerous honors and acknowledgements for his work on characterizing extracellular matrix proteins and their role in muscle function, including the EndDuchenne Award from Parent Project Muscular Dystrophy. He is also a recipient of numerous NIH grant awards and serves on the Scientific Advisory Boards of two patient advocacy groups. He also chaired the Biomarkers Working Group and was a member of the Steering Committee for the recent PPMD initiative to develop Guidance for Industry for developing therapeutics for DMD.

Charles Polsky, MD – Director

Dr. Polsky is a professional Life Sciences investor and currently serves as Director of Equities at Chicago-based William Harris Investors. Over the past decade, he has served on numerous early-stage biotech boards, and has managed a portfolio of early-stage biotech investments. In addition to his professional work, Dr. Polsky volunteers his time as a mentor for Chicago Innovation Mentors and also as an investment consultant for the University of Chicago Innovation Fund. He is boarded in Internal Medicine.